Relevance: GS-2 (Health & Social Justice) & GS-3 (Economy, Science & Technology, Intellectual Property) |Source: The Indian Express

1. What is the News?

The Indian pharmaceutical sector is witnessing a massive expansion. In just one month, the market for diabetes and weight-loss drugs (GLP-1 category) grew by over 75%.

• The Trigger: On March 21, 2026, the global giant Novo Nordisk lost its patent for Semaglutide (the active molecule in famous brands like Ozempic).
• The Result: Indian generic companies immediately entered the market, causing sales to jump from 25,000 units in February to 1.7 lakh units in April.

2. The Science: How do these Drugs Work?

These medicines are known as Incretin Mimetics. They are designed to copy the action of natural hormones found in our gut.

• Stimulate Insulin: they prompt the pancreas to release insulin only when blood sugar levels are high.
• Block Glucagon: They stop the liver from releasing extra sugar into the bloodstream.
• Slow Digestion: This is the “weight loss” secret. They slow down gastric emptying (the speed at which the stomach clears food), making a person feel full for much longer.
• Semaglutide vs. Tirzepatide: While Semaglutide targets one hormone receptor (GLP-1), the newer Tirzepatide targets two (GLP-1 and GIP), often leading to even greater weight loss.

3. Market Dynamics & The “Patent Cliff”

In pharmaceutical terms, a “Patent Cliff” occurs when a drug’s patent expires, allowing cheaper versions to flood the market.

• Market Expansion: Usually, generics replace the expensive original. Here, they actually grew the whole market. Expensive “innovator” drugs still sold well, but cheaper generics reached a massive new group of people.
• Affordability: Generics are significantly cheaper. While the revenue is split between the original and generic companies, the volume (number of people being treated) is much higher with generics.
• Indian Leadership: Torrent Pharmaceuticals has emerged as a leader because it launched an oral (pill) version, while many competitors currently offer only injections.

4. Why This is Significant for India

• The Dual Epidemic: India is the “Diabetes Capital of the World,” with over 100 million diabetics and a rising obesity crisis.
• Preventive Healthcare: Obesity is a root cause of Non-Communicable Diseases (NCDs) like heart attacks and strokes. Making these drugs affordable acts as “preventive care,” reducing the long-term burden on our hospitals.
• Democratizing Health: Previously, these advanced medicines were only for the wealthy elite. Now, the common man can access life-changing technology.

5. Important Administrative & Legal Frameworks

To score well in the Mains, use these formal terms:

• The Patents Act, 1970 (Section 3d): This famous Indian law prevents “evergreening” (companies making tiny, non-innovative changes to a drug just to extend their 20-year monopoly). It allows Indian companies to launch generics the moment a core patent expires.
• CDSCO: The apex body that approves the safety and quality of these new medicines in India.
• NPPA: The government body that monitors drug prices to ensure they stay affordable for the public.
• NPCDCS: India’s flagship national programme to control cancer, diabetes, and strokes. Cheap GLP-1 drugs fit perfectly into this public health mission.

UPSC Value Box

• Incretins: Natural gut hormones that help the body manage blood sugar and fullness.
• Non-Communicable Diseases (NCDs): Chronic diseases like diabetes and heart disease that are caused by lifestyle/genetics rather than infections.
• Evergreening: A legal strategy used by pharma companies to extend their patent monopoly by making minor tweaks to a drug.

With reference to GLP-1 drugs and the Indian pharmaceutical landscape, consider the following statements:

1. GLP-1 drugs, also known as incretin mimetics, primarily work by accelerating gastric emptying to improve digestion.
2. Section 3(d) of the Indian Patents Act, 1970, is a provision designed to prevent the “evergreening” of pharmaceutical patents.
3. The National Pharmaceutical Pricing Authority (NPPA) is the nodal body responsible for approving the clinical efficacy and safety of new generic formulations in India.

Which of the statements given above is/are correct?

(a) 1 and 2 only

(b) 2 only

(c) 2 and 3 only

(d) 1, 2 and 3

Correct Answer: (b)